SS-31 (Elamipretide, formerly Bendavia) is a mitochondria-targeted tetrapeptide that represents one of the most advanced mitochondrial therapeutics in clinical development. Designed by Dr. Hazel Szeto at Weill Cornell Medicine, SS-31 selectively accumulates in the inner mitochondrial membrane where it stabilizes cardiolipin-dependent electron transport chain organization. By restoring mitochondrial bioenergetics and reducing reactive oxygen species production, SS-31 addresses a fundamental mechanism of cellular aging and disease across multiple organ systems.
Mitochondrial Targeting Design
SS-31 belongs to the Szeto-Schiller (SS) peptide family, characterized by an alternating aromatic-cationic amino acid motif. The sequence D-Arg-2′,6′-dimethyltyrosine(Dmt)-Lys-Phe-NH2 is designed for cell membrane penetration and mitochondrial accumulation. The peptide crosses plasma membranes through energy-independent mechanisms (likely direct translocation) and concentrates 1,000-5,000 fold in the inner mitochondrial membrane (IMM), driven by the mitochondrial membrane potential (~-180 mV).
The D-arginine residue confers protease resistance. The dimethyltyrosine (Dmt) residue provides both the aromatic character needed for membrane interaction and direct antioxidant activity (the phenolic hydroxyl can scavenge reactive oxygen species). C-terminal amidation increases metabolic stability. These design features give SS-31 a half-life of hours rather than minutes.
Cardiolipin Interaction
SS-31’s primary molecular target is cardiolipin (CL), a unique phospholipid found almost exclusively in the inner mitochondrial membrane. Cardiolipin contains four fatty acid chains (typically linoleic acid in the heart) and plays essential structural and functional roles: it anchors electron transport chain (ETC) complexes in the IMM, facilitates supercomplex formation (respirasomes), supports cytochrome c binding, and maintains cristae morphology.
During aging and disease, cardiolipin undergoes peroxidation (oxidative damage to its unsaturated fatty acid chains) and remodeling that disrupts ETC organization. This leads to electron leak from the ETC, increasing superoxide production and reducing ATP synthesis efficiency. SS-31 binds cardiolipin at the ETC complex interface, stabilizing supercomplex organization and reducing electron leak. The result is improved ATP production and reduced reactive oxygen species (ROS) generation—addressing both energy deficit and oxidative stress simultaneously.
Preclinical Evidence
In aged mice, SS-31 treatment restored mitochondrial function across multiple organs. Cardiac studies showed improved diastolic function, reduced hypertrophy, and enhanced exercise tolerance. Skeletal muscle studies demonstrated improved mitochondrial coupling efficiency, increased ATP production, and enhanced exercise capacity—reversing age-related mitochondrial dysfunction within weeks of treatment.
Renal ischemia-reperfusion injury models showed SS-31 protection against mitochondrial damage, reduced apoptosis, and improved kidney function recovery. In retinal models, SS-31 preserved photoreceptor function and retinal ganglion cell survival under oxidative stress conditions.
Clinical Development
Stealth BioTherapeutics (now Larimar Therapeutics) advanced elamipretide through multiple clinical programs. The most promising results came from Barth syndrome—a rare genetic disorder caused by tafazzin mutations that impair cardiolipin remodeling. In the TAZPOWER trial, elamipretide improved six-minute walk distance, a validated functional endpoint. The FDA granted elamipretide Fast Track designation for Barth syndrome.
Heart failure with preserved ejection fraction (HFpEF) trials showed mixed results, with improvements in some endpoints (E/e’ ratio on echocardiography) but not the primary endpoint (six-minute walk distance) in the Phase 2 EMBRACE trial. Primary mitochondrial myopathy trials showed trends toward functional improvement. Age-related macular degeneration (dry AMD) trials showed stabilization of visual function.
Aging Research Implications
SS-31’s ability to reverse age-related mitochondrial dysfunction positions it at the center of longevity research. Mitochondrial dysfunction is one of the nine hallmarks of aging, and it drives multiple other hallmarks including cellular senescence, stem cell exhaustion, and altered intercellular communication. By restoring mitochondrial function, SS-31 may produce systemic anti-aging effects. See our NAD+ Peptide Research for complementary mitochondrial approaches.
Frequently Asked Questions
What is SS-31?
A mitochondria-targeted tetrapeptide (Elamipretide) that stabilizes electron transport chain function by interacting with cardiolipin in the inner mitochondrial membrane.
How does SS-31 target mitochondria?
Its alternating aromatic-cationic motif enables membrane crossing and 1,000-5,000 fold concentration in mitochondria driven by membrane potential. It binds cardiolipin to stabilize ETC supercomplexes.
What clinical trials have tested SS-31?
Trials for Barth syndrome (strongest data), HFpEF, primary mitochondrial myopathy, dry AMD, and renal injury. Results strongest in cardiolipin-deficiency conditions.